

♦ GLKVs13 (iPS cells expressing the second highest HLA in Japan※1)

Clone ID	GLKVs13	Product	Human iPS cells
Source	Cord blood, Human	Race	Japanese
Passage No.	7	Gender	Male
Lot No.	20170929-02	Manufacture Dates	Sep. 29 ^{th,} 2017
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG
Culture Method	Feeder-free (**2)		
Plasmids for	pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, pCXB-EBNA1		
reprograming			
Use and Provision	Please check our web site ;		
of this cell stock	https://www.cira-foundation.or.jp/e/project/stock.html		

^(%1) **Reference**; Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

Test Result

Test	Method	Result
Sterility	BacT/ALERT	Negative
Mycoplasma	PCR	Negative
Endotoxin	LAL	≦ 5 EU/mL
Virus		
(HBV, HCV, HIV, HTLV,	PCR	Negative
Parvovirus B19)		
HLA typing	PCR-SBT	Consistent with the donor cells
(HLA-A, B, DR)	PUR-ODI	Consistent with the donor cens
STR genotyping	PCR	Consistent with the donor cells
Morphology	Microscope	Consistent with human ES cells
	Conventional Giemsa	
Karyotype	analysis	46,XY[20]
	G-banding	
Plasmid remnants	qPCR	Below the limit of quantification
CNV ^(※3)	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.85) and Shibata list ^(※5) .
SNV/Indel ^(※4)	WGS, WES	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.85) and Shibata list ^(**5) .
I In differentiated	Microarray ^(※7)	POU5F1: 4.3%、NANOG: 9.3% (Relative expression levels of GAPDH)
Undifferentiated markers	Flow cytometry (**7)	TRA-1-60: 97.8% SSEA4: 99.6% TRA-2-49: 99.5%


^(%2) Reference; Nakagawa, et. al., Nat Biotechnol. 2008 26(1):101-106



	Counting the number of the	
Thawed postnatal cells	cells with a disposable	1.45 × 10 ⁵ cells (Survival rate ;69.3%)
	hemocytometer (**6,7)	
	Counting the number of the	
Number of proliferating	cells with a disposable	15.8×10^5 cells (Number of seeded cells: 1.39
cells after thawing	hemocytometer after	× 10 ⁵ cells)
	culturing for 7 days(*6,7).	
	Counting the number of the cells (**6,7)	P10→P11: 31.6
		P11→P12: 26.0
Doubling time (h)		P12→P13: 33.8
		P13→P14: 38.1
		P14→P15: 32.8

- (%3) CNV; Copy Number Variation
- (¾4) SNV/Indel; Single nucleotide variants /Insertion Deletion
- (%5) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)
- (%6) OLYMPUS Cell Counter model R1
- (※7) The result of # 1 out of 3 frozen stocks is shown.

■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)

